In a nonrandomized, single-arm trial evaluating sunitinib in patients with advanced GIST, imatinib-resistant secondary mutations within the KIT activation loop (detected in single-tumor biopsies) were associated with rapid clinical progression (median PFS, 2.3 months), whereas PFS was significantly longer for patients with secondary mutations in the KIT ATP-binding pocket (median PFS, 7.8 months; P = 0.0157)11. This evidence concerns the gene KIT and gastrointestinal stromal tumor.